Studybox Research 510(k) Clinical Studies
Point-of-Care BNP / NT-proBNP Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Natriuretic peptide tests are cleared as an aid in the diagnosis of heart failure in patients presenting with dyspnea, and the clinical study follows that intended use directly: patients with acute dyspnea are enrolled, the device is run, and a blinded panel of cardiologists adjudicates whether heart failure was the cause using clinical criteria, imaging and the full record. Sensitivity and specificity at the proposed cutoffs are then reported, with age stratification for NT-proBNP because its normal range rises with age.
A point-of-care version is typically compared to a cleared laboratory assay as well, so the study has both a method comparison and a clinical performance component. Whole blood versus plasma agreement and the effect of hematocrit are specific to the point-of-care format, and the rule-out cutoffs used in heart failure guidelines are where agreement matters most.
- Analyte
- B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP)
- Therapeutic area
- Cardiovascular Disease
- Specimens
- Venous Whole Blood, Serum and Plasma, Capillary Fingerstick Blood
- Intended-use settings
- emergency department, hospital POC, physician office, urgent care
- Operators
- Emergency department, hospital point-of-care and clinic staff, typically nurses and clinical technicians.
- Comparator
- Typically an FDA-cleared laboratory BNP or NT-proBNP assay for method comparison, and an adjudicated clinical diagnosis of heart failure (based on established clinical criteria and imaging) for clinical performance.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- Adjudication of heart failure as the cause of dyspnea is the clinical reference; the protocol should define the criteria, the adjudicators' blinding and how patients with mixed etiologies are classified.
- Cutoffs and age strata in labeling must be supported by the clinical study population; for NT-proBNP, the age-stratified rule-in cutoffs and the single rule-out cutoff are each evaluated.
- Renal function, obesity and atrial fibrillation affect natriuretic peptide levels, and reviewers expect subgroup data or labeling statements addressing them.
- Monitoring or prognostic claims (serial measurement, risk stratification) are separate claims requiring longitudinal data and are not supported by a dyspnea diagnostic study.
Endpoints the study must support
- Clinical sensitivity and specificity for heart failure in patients presenting with dyspnea at the proposed cutoff(s), typically age-stratified for NT-proBNP, with 95% confidence intervals
- Method comparison and imprecision against the laboratory assay across the measuring range
- Agreement across claimed specimen matrices (whole blood versus plasma)
Enrollment realities
Driven by adjudicated heart failure cases among dyspneic presentations, a substantial minority in emergency departments; office-based enrollment yields fewer acute cases. Adjudication requires complete records including echocardiography, which constrains site selection.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Relevant FDA guidance
FAQ
Point-of-Care BNP / NT-proBNP Test Study Questions.
01 Who operates the point-of-care bnp / nt-probnp test in a 510(k) studies study?
Emergency department, hospital point-of-care and clinic staff, typically nurses and clinical technicians.
02 What is the comparator for a point-of-care bnp / nt-probnp test study?
Typically an FDA-cleared laboratory BNP or NT-proBNP assay for method comparison, and an adjudicated clinical diagnosis of heart failure (based on established clinical criteria and imaging) for clinical performance.
03 What drives enrollment for a point-of-care bnp / nt-probnp test study?
Driven by adjudicated heart failure cases among dyspneic presentations, a substantial minority in emergency departments; office-based enrollment yields fewer acute cases. Adjudication requires complete records including echocardiography, which constrains site selection.
Let's talk IVD research
Planning a point-of-care bnp / nt-probnp test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.